| Similar Articles |
|---|
 |
The Motley Fool
March 22, 2010
Brian Orelli |
Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio.   |
The Motley Fool
November 2, 2009
Brian Orelli |
Winners and Losers of the House Health-Care Reform Bill There's something for everyone to hate. |
BusinessWeek
May 20, 2009
Maria Bartiromo |
Pfizer's Kindler on Health-Care Reform and the Wyeth Deal Pfizer's CEO discusses its acquisition of Wyeth and its plan to provide some drugs for free to those without jobs and insurance. |
The Motley Fool
January 26, 2011
Brian Orelli |
Health-Care Reform Lives: Here's Where to Invest State of the Union turned investment thesis regarding health insurance companies. |
The Motley Fool
May 28, 2010
Brian Orelli |
Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree. |
The Motley Fool
February 27, 2009
Brian Orelli |
Can $634 Billion Save the U.S. Health Care System? The good news is that Obama's budget includes a $634 billion down payment on getting insurance for the 48 million uninsured. The bad news is that the president has to pay for that by cutting costs in other areas. |
The Motley Fool
July 23, 2010
Bryan White |
3 Buys Suffering From the Health-Care Hangover Three ideas in value territory for a much-needed sector. |
The Motley Fool
May 12, 2009
Brian Orelli |
Your Company Is Giving Away Revenue Bad news for investors in the health-care industry: the companies you invest in just pledged to give back 1.5% of their expected U.S. revenue growth to President Obama. |
The Motley Fool
August 26, 2010
Brian Orelli |
Drug Prices Up, but Don't Read Too Much Into It AARP is out with its annual report on the cost of medications, and it's more of the same: bad news if you're a consumer, but good news if you're invested in drugmakers. |
The Motley Fool
December 30, 2010
Brian Orelli |
This NICE Deal Could Foreshadow 2011 Value-based pricing is coming. The only way to encourage lower drug costs is to get the end user to pay the cost directly. |
The Motley Fool
December 3, 2009
Brian Orelli |
Health-Care Reform Is Very Taxing On the industries that keep us alive. |
The Motley Fool
June 30, 2009
Brian Orelli |
A Cocktail for Drug Investors Drug cocktails aren't just for alchemists anymore. In many diseases they've become big business, and pharmaceutical investors would be smart to pay attention. |
The Motley Fool
June 19, 2009
Brian Orelli |
Comparative Medicine Could Sink Your Stocks The government's plan will have a very unpredictable effect on companies. |
The Motley Fool
February 12, 2009
Brian Orelli |
Stimulus Could Be Bitter Pill for Some Investors Health-care shareholders need to watch provisions of the stimulus bill closely. |
The Motley Fool
November 7, 2008
Brian Orelli |
Will Obama Make Your Portfolio Healthy? The changes coming in the health-care industry could be a mixed bag of good and bad for your portfolio. |
The Motley Fool
November 30, 2011
Brian Orelli |
This $581 Doughnut Hole Costs Drugmakers It's costing drugmakers money. Can they recoup it elsewhere? |
Pharmaceutical Executive
December 1, 2008
Jill Wechsler |
Challenge and Challenges Expanded healthcare coverage also fits the goals of pharma manufacturers. |
BusinessWeek
May 10, 2004
John Carey |
Drug Prices: A New Covenant? The states' growing negotiating clout with Big Pharma raises crucial questions |
The Motley Fool
April 22, 2009
Selena Maranjian |
Will Health-Care Reform Hurt Investors? The bad news here is that there's quite a bit of uncertainty around this issue, and that some health-care-focused companies may end up suffering. Read on to see who. |
The Motley Fool
July 31, 2009
Brian Orelli |
A Health-Care Investor's Nightmare When it comes to health-care reform, no news is not good news; the House's recent plan to delay voting on a health-care reform bill until September should have investors reaching for the antacids. |
The Motley Fool
April 26, 2011
Brian Orelli |
There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost. |
The Motley Fool
September 20, 2007
Brian Orelli |
Winners and Losers in Universal Health Care Here's a look at the companies that stand to win or lose if Hillary Rodham Clinton is elected -- and gets her three-pronged health-care reform plan through Congress. |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
CFO
Kris Frieswick |
Clinical Trials A new kind of pricing pressure puts pharmaceutical CFOs in an unfamiliar role: evangelist... |
BusinessWeek
October 22, 2009
Sasseen & Arnst |
Who Picks Up the Tab for Health Reform Insurers and taxpayers are likely to pay big chunks of the $900 billion bill to overhaul the nation's health-care system. Doctors will feel the least pain. |
Reason
April 2001
Ronald Bailey |
Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry? |
Pharmaceutical Executive
February 1, 2007
Patrick Clinton |
From the Editor: Meaningless A bill requiring the Secretary of Health and Human Services to negotiate Medicare drug prices directly with pharmaceutical manufacturers has a fatal flaw. |
The Motley Fool
January 28, 2010
Brian Orelli |
Health-Care Reform Is Dead. Probably. Breaking up the bill doesn't seem like the answer. What do insurers and pharmaceutical companies have to say? |
BusinessWeek
October 18, 2004
Catherine Arnst |
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
The Motley Fool
April 21, 2009
Brian Orelli |
Reworking the Broken R&D Model When it comes to drug development, it's becoming increasingly clear that competition isn't always the best thing for the industry. Collaborations will help bring drugs to the market more cheaply. |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
Pharmaceutical Executive
February 1, 2014
Jill Wechsler |
Drug Coverage, Costs Under Scrutiny Benefits offered by insurance plans on health exchanges and through Medicare are raising concerns about patient access to needed therapies |
The Motley Fool
September 10, 2009
Brian Orelli |
Obamacare: Something for Everyone to Hate Health insurers saw more to love, though. |
The Motley Fool
March 30, 2009
Brian Orelli |
Change the Game? Change the Rules! There are ways for investors to get around Obama's plan to lower health care costs. Investing in drug companies in this time of "change" doesn't have to be scary. You've just got to find rule breaker-type drugmakers, because playing by the rules isn't going to cut it anymore. |
BusinessWeek
November 29, 2004
Catherine Arnst |
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. |
The Motley Fool
December 10, 2009
Brian Orelli |
The Public Option Is Dead. Again. Maybe. So why haven't health insurers' stocks rebounded? |
The Motley Fool
March 17, 2008
Brian Orelli |
Drugmakers That Make Rivals Green with Envy A look at some drugmakers with cash to spend: Pfizer...Wyeth... Novartis... Amylin Pharmaceuticals... Elan...Vertex Pharmaceuticals... Exelixis... |
The Motley Fool
May 12, 2010
Matt Koppenheffer |
Are Health-Care Stocks a Buy? Health-care stocks have underperformed the market so far this year. Is it time for a turnaround? |
The Motley Fool
March 12, 2010
Brian Orelli |
Insurers to Washington: We're Not the Problem Insurers say they're a small piece of the problem pie. |
The Motley Fool
December 24, 2009
Brian Orelli |
Health-Care Reform: Two-Thirds Finished The U.S. Senate voted this morning to pass the health-care reform bill, moving us closer to capping off the long process that's weighed on health-care and insurance stocks this year. |
Pharmaceutical Executive
January 1, 2014
Jill Wechsler |
Pharma Challenges for 2014 Pricing and personalized medicine are key themes shaping drug development and marketing |
Pharmaceutical Executive
February 1, 2009
Jill Wechsler |
Securing Savings A close look at the healthcare industry will separate real cost-cutting measures from money-saving myths. |
The Motley Fool
January 8, 2008
Brian Orelli |
Brits May Bludgeon Drug Companies The U.K.'s National Health Service delivers a shock to drugmakers; it is considering a 10% drop in the rate that it pays for drugs, to help it reach its goal of a 3% reduction in the nation's overall health-care bill. |
The Motley Fool
February 26, 2009
Brian Orelli |
Obama's Uncertainty Is Unhealthy for Investors There was lots of talk about health care reform in the President's speech before Congress and the nation, but investors are still in a wait-and-see mode. |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
Managed Care
July 2003
John Carroll |
CMS Move Threatens To Put Orphan Drugs Out in Cold Have drug companies lost the incentive to develop products for small populations? What's managed care's stake? |
Pharmaceutical Executive
October 1, 2008
Jill Wechsler |
Part D Under Attack Congressional leaders ready campaign to curb Medicare drug plans. |
The Motley Fool
February 9, 2010
Brian Orelli |
What Bipartisan Health-Care Reform Means for Investors Republicans and Democrats will debate on TV, but little may come of it. |
